Mar 11 |
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
|
Mar 7 |
11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds
|
Mar 5 |
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
|
Mar 4 |
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
|
Feb 20 |
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom
|
Feb 20 |
LTRN: Spotlighting ADCs & Another Orphan
|
Feb 15 |
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
|
Feb 5 |
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
|
Jan 17 |
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
|
Dec 13 |
The 3 Most Undervalued AI Penny Stocks to Buy in December
|